Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on September 14, 2020, covering events occurring on September 10, 2020. The Company is a Delaware corporation headquartered in Nashville, Tennessee, with common stock trading on the NASDAQ Global Market under the symbol HROW.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory events rather than periodic financial performance data.
Material Changes and Events
- Regulatory Decision: On September 10, 2020, Imprimis NJOF, LLC, a wholly-owned subsidiary of Harrow Health, received correspondence from the Centers for Medicare and Medicaid Services (CMS).
- Rejection Details: CMS rejected Imprimis' application for transitional pass-through status under the hospital outpatient prospective payment system for one of its compounded products.
- Operational Impact: The Company explicitly states that this decision does not affect current operations, revenues, cash flows, or the availability of the compounded product, which will continue to be sold in its current form.
- Regulation FD Disclosure: The filing includes a corporate presentation (Exhibit 99.1) used by management at investor conferences, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or forward-looking projections. The primary risk disclosed is the regulatory rejection regarding payment status for a specific compounded product, though management has characterized the immediate financial impact as negligible.
Investor Verification Checklist
- Verify the specific compounded product affected by the CMS rejection to assess long-term pricing implications.
- Review the attached Exhibit 99.1 (Corporate Presentation) for any non-filed strategic updates or market commentary.
- Monitor future filings for any changes in the Company's stance regarding the availability or pricing of the affected product.
- Confirm that the rejection does not trigger any contractual obligations with hospital partners regarding payment terms.